These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12694084)

  • 1. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.
    Ladabaum U
    Aliment Pharmacol Ther; 2003 Apr; 17(8):1021-30. PubMed ID: 12694084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
    Camilleri M; Mayer EA; Drossman DA; Heath A; Dukes GE; McSorley D; Kong S; Mangel AW; Northcutt AR
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1149-59. PubMed ID: 10468696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
    Olden K; DeGarmo RG; Jhingran P; Bagby B; Decker C; Markowitz M; Carter E; Bobbitt W; Dahdul A; DeCastro E; Gringeri L; Johanson J; Levinson L; Mula G; Poleynard G; Stoltz RR; Truesdale R; Young D;
    Am J Gastroenterol; 2002 Dec; 97(12):3139-46. PubMed ID: 12492201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
    Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
    Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lotronex(tm): therapy for diarrhea predominant irritable bowel syndrome.
    McGahan L
    Issues Emerg Health Technol; 2000 Oct; (11):1-5. PubMed ID: 11902219
    [No Abstract]   [Full Text] [Related]  

  • 10. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.
    Lewis JH
    Expert Rev Gastroenterol Hepatol; 2010 Feb; 4(1):13-29. PubMed ID: 20136586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.
    Palmer RH
    BMJ; 2003 Jan; 326(7379):51. PubMed ID: 12518769
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Cremonini F; Delgado-Aros S; Camilleri M
    Neurogastroenterol Motil; 2003 Feb; 15(1):79-86. PubMed ID: 12588472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.
    Cremonini F; Nicandro JP; Atkinson V; Shringarpure R; Chuang E; Lembo A
    Aliment Pharmacol Ther; 2012 Sep; 36(5):437-48. PubMed ID: 22779693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.
    Camilleri M; Northcutt AR; Kong S; Dukes GE; McSorley D; Mangel AW
    Lancet; 2000 Mar; 355(9209):1035-40. PubMed ID: 10744088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
    Lynd LD; Najafzadeh M; Colley L; Byrne MF; Willan AR; Sculpher MJ; Johnson FR; Hauber AB
    Value Health; 2010; 13(4):411-7. PubMed ID: 19744297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.
    Chang L; Chey WD; Harris L; Olden K; Surawicz C; Schoenfeld P
    Am J Gastroenterol; 2006 May; 101(5):1069-79. PubMed ID: 16606352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.
    Watson ME; Lacey L; Kong S; Northcutt AR; McSorley D; Hahn B; Mangel AW
    Am J Gastroenterol; 2001 Feb; 96(2):455-9. PubMed ID: 11232690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients.
    Jones RH; Holtmann G; Rodrigo L; Ehsanullah RS; Crompton PM; Jacques LA; Mills JG
    Aliment Pharmacol Ther; 1999 Nov; 13(11):1419-27. PubMed ID: 10571597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?
    Andresen V; Hollerbach S
    Drug Saf; 2004; 27(5):283-92. PubMed ID: 15061683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.